About Transenterix (NYSEAMERICAN:TRXC)
TransEnterix, Inc. is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company's ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera. The system features advanced technology to enable surgeons with haptic feedback and the ability to move the camera through eye movement. The system replicates laparoscopic motion and integrates three-dimensional high definition (3DHD) vision technology. The ALF-X System also offers responsible economics to hospitals by offering robotic technology with reusable instruments. The SurgiBot System is designed as a single-incision, patient-side robotic-assisted surgery system. The Company also develops and manufactures laparoscopic surgical instruments that are used in abdominal surgery, such as scissors, graspers, clip appliers, and suction and irrigation instruments.
Industry, Sector and Symbol:
- Industry: Medical Equipment, Supplies & Distribution
- Sub-Industry: N/A
- Sector: Medical Equipment, Supplies & Distribution - NEC
- Symbol: NYSEAMERICAN:TRXC
- CUSIP: N/A
- Web: www.transenterix.com
- Trailing EPS: ($0.62)
- Net Margins: -928.85%
- Return on Equity: -49.16%
- Return on Assets: -33.51%
- Outstanding Shares: 148,540,000
Frequently Asked Questions for Transenterix (NYSEAMERICAN:TRXC)
What is Transenterix's stock symbol?
Transenterix trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "TRXC."
How were Transenterix's earnings last quarter?
Transenterix Inc (NYSEAMERICAN:TRXC) announced its earnings results on Monday, March, 6th. The medical instruments supplier reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.01. Transenterix had a negative return on equity of 49.16% and a negative net margin of 928.85%. View Transenterix's Earnings History.
Where is Transenterix's stock going? Where will Transenterix's stock price be in 2017?
3 Wall Street analysts have issued twelve-month price targets for Transenterix's stock. Their forecasts range from $0.70 to $5.00. On average, they anticipate Transenterix's share price to reach $3.23 in the next twelve months. View Analyst Ratings for Transenterix.
Are investors shorting Transenterix?
Transenterix saw a increase in short interest in October. As of October 31st, there was short interest totalling 9,857,271 shares, an increase of 16.2% from the October 13th total of 8,480,583 shares. Based on an average trading volume of 34,701,062 shares, the days-to-cover ratio is presently 0.3 days. Currently, 10.2% of the shares of the stock are short sold.
Who are some of Transenterix's key competitors?
Some companies that are related to Transenterix include Given Imaging (GIVN), Orthofix International N.V. (OFIX), OraSure Technologies (OSUR), Intersect ENT (XENT), K2M Group Holdings (KTWO), Cardiovascular Systems (CSII), Landauer (LDR), CryoLife (CRY), STAAR Surgical Company (STAA), Meridian Bioscience (VIVO), AtriCure (ATRC), Exactech (EXAC), Invacare Corporation (IVC), Consort Medical plc (CSRT), Surmodics (SRDX), Syneron Medical (ELOS), Antares Pharma (ATRS) and Utah Medical Products (UTMD).
Who are Transenterix's key executives?
Transenterix's management team includes the folowing people:
- Paul A. LaViolette, Independent Chairman of the Board (Age 58)
- Todd M. Pope, President, Chief Executive Officer, Director (Age 49)
- Joseph P. Slattery CPA, Chief Financial Officer, Executive Vice President, IR Contact Officer (Age 50)
- Anthony Fernando, Chief Operating Officer
- Andrea Biffi, Director
- Dennis J. Dougherty, Independent Director (Age 56)
- Jane H. Hsiao Ph.D., Independent Director (Age 69)
- William N. Kelley M.D., Independent Director (Age 77)
- Aftab R. Kherani M.D., Independent Director (Age 41)
Who owns Transenterix stock?
Transenterix's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Ladenburg Thalmann Financial Services Inc. (0.05%). Company insiders that own Transenterix stock include Andrea Biffi, Anthony C J Fernando, Joseph P Slattery, Richard C Pfenniger Jr, SPA Sofar, Todd Pope and Willam N Kelley. View Institutional Ownership Trends for Transenterix.
Who bought Transenterix stock? Who is buying Transenterix stock?
Transenterix's stock was acquired by a variety of institutional investors in the last quarter, including Ladenburg Thalmann Financial Services Inc.. Company insiders that have bought Transenterix stock in the last two years include Andrea Biffi, Anthony C J Fernando, Joseph P Slattery, Richard C Pfenniger Jr, SPA Sofar and Willam N Kelley. View Insider Buying and Selling for Transenterix.
How do I buy Transenterix stock?
Shares of Transenterix can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Transenterix's stock price today?
One share of Transenterix stock can currently be purchased for approximately $2.49.
How big of a company is Transenterix?
Transenterix has a market capitalization of $535.96 million.
How can I contact Transenterix?
Transenterix's mailing address is 635 Davis Dr Ste 300, MORRISVILLE, NC 27560-7199, United States. The medical instruments supplier can be reached via phone at +1-919-7658400.
MarketBeat Community Rating for Transenterix (NYSEAMERICAN TRXC)MarketBeat's community ratings are surveys of what our community members think about Transenterix and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Transenterix (NYSEAMERICAN:TRXC) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 1 Hold Rating, 2 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 2.67)|
|Consensus Price Target: ||$3.23|
Consensus Price Target History for Transenterix (NYSEAMERICAN:TRXC)
Analysts' Ratings History for Transenterix (NYSEAMERICAN:TRXC)
(Data available from 11/18/2015 forward)
|10/31/2017||Stifel Nicolaus||Boost Price Target||Buy||$3.75 -> $4.00|
|10/20/2017||Ladenburg Thalmann Financial Services||Set Price Target||Buy||$5.00|
|1/19/2017||Raymond James Financial, Inc.||Downgrade||Outperform -> Mkt Perform|
|5/16/2016||Sterne Agee CRT||Reiterated Rating||Buy|
|5/11/2016||Lake Street Capital||Downgrade||Buy -> Hold||$2.00|
|4/18/2016||BTIG Research||Downgrade||Buy -> Neutral||$6.00|
Earnings History and Estimates Chart for Transenterix (NYSEAMERICAN:TRXC)
Earnings History by Quarter for Transenterix (NYSEAMERICAN TRXC)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/9/2016||Q316||($0.10)||($0.11)||$1.80 million||$1.50 million||View||Listen|
|2/24/2015||Q414||($0.18)||($0.13)||$50.00 million||$0.13 million||View||N/A|
|11/6/2014||Q3||($0.18)||($0.18)||$0.10 million||$0.06 million||View||N/A|
Earnings Estimates for Transenterix (NYSEAMERICAN:TRXC)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Transenterix (NYSEAMERICAN:TRXC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Transenterix (NYSEAMERICAN TRXC)
Insider Trades by Quarter for Transenterix (NYSEAMERICAN TRXC)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|11/16/2017||Joseph P Slattery||CFO||Sell||529,609||$2.80||$1,482,905.20|| |
|11/14/2017||Joseph P Slattery||CFO||Sell||333,000||$2.93||$975,690.00|| |
|10/18/2017||Todd Pope||Insider||Sell||600,000||$3.68||$2,208,000.00|| |
|8/8/2017||Willam N Kelley||Director||Buy||30,000||$0.71||$21,300.00|| |
|5/16/2017||Richard C Pfenniger Jr||Director||Buy||100,000||$0.54||$54,000.00|| |
|1/4/2017||S.P.A Sofar||Major Shareholder||Buy||3,722,685||$1.40||$5,211,759.00|| |
|8/22/2016||Andrea Biffi||Director||Buy||40,000||$1.40||$56,000.00|| |
|6/14/2016||Anthony C J Fernando||CTO||Buy||27,000||$1.46||$39,420.00|| |
|5/13/2016||Joseph P Slattery||CFO||Buy||50,000||$1.92||$96,000.00|| |
|11/16/2015||Andrea Biffi||Director||Buy||25,000||$2.81||$70,250.00|| |
|11/13/2015||Willam N Kelley||Director||Buy||20,000||$2.80||$56,000.00|| |
|11/12/2015||Joseph P Slattery||CFO||Buy||15,000||$2.77||$41,550.00|| |
|10/2/2014||Joseph P Slattery||CFO||Sell||33,000||$4.19||$138,270.00|| |
|9/8/2014||Richard Mueller||COO||Sell||3,000||$3.60||$10,800.00|| |
|9/8/2014||Todd Pope||CEO||Sell||50,000||$3.70||$185,000.00|| |
|4/21/2014||Aisling Capital Iii Lp||Major Shareholder||Buy||1,037,767||$4.00||$4,151,068.00|| |
|4/21/2014||William N Starling Jr||Director||Buy||221,450||$4.00||$885,800.00|| |
Headline Trends for Transenterix (NYSEAMERICAN:TRXC)
Latest Headlines for Transenterix (NYSEAMERICAN TRXC)
Transenterix (NYSEAMERICAN TRXC) Chart for Saturday, November, 18, 2017